FDA Finalizes FY 2026 OTC User Fee and Facility Registration Guidance
Institutional Regulatory Framework for the OTC Market Established
The U.S. Food and Drug Administration (FDA) has finalized the amendments to the OTC Monograph Drug User Fee Act (OMUFA) for Fiscal Year (FY) 2026, including facility fees and registration procedures for over-the-counter (OTC) monograph drugs. This is a crucial step in establishing the financial foundation that enables the regulatory agency to efficiently review the safety and efficacy of OTC products. In particular, this revision allows OTC manufacturers to establish a more systematic U.S. market entry strategy within a predictable regulatory environment. The FDA aims to operate the fee system transparently, ultimately providing consumers with safe and readily available medications.
Enhanced Cost Predictability through Differentiated Fees Based on Facility Size
The finalized fee structure for FY 2026 sets the annual fee for OTC Monograph Drug Facilities (MDFs) at $19,188. Contract Manufacturing Organizations (CMOs) will pay a lower fee of $12,792, which is expected to alleviate the cost burden on small and medium-sized contract manufacturers. This tiered fee system can be analyzed as a market-friendly mechanism that encourages both large pharmaceutical companies and small manufacturers to participate stably in the U.S. OTC production ecosystem. Companies must diligently pay the corresponding fees based on facilities registered between January 1 and December 31, 2025, to avoid penalties.
Fees for New Drug and Ingredient Additions through OMOR Applications
In addition to facility fees, fees for OTC Monograph Order Requests (OMORs) for adding new OTC ingredients or indications have also been finalized. The application fee for Tier 1 OMORs, which require more complex reviews, is set at $587,529, requiring companies to make significant financial considerations when launching innovative new products. Tier 2 OMOR fees, which are less complex, are set at $117,505, helping to facilitate administrative convenience for minor changes such as label information updates. This increase in fees will drive a qualitative change, encouraging pharmaceutical companies to focus on developing products with guaranteed marketability rather than simple imitation products when introducing new pipelines.
Strict Deadlines and Regulatory Risks for Non-Payment
The payment deadline for the OMUFA facility fees is June 1, 2026, and all payments must be made electronically, with no paper checks accepted. Failure to pay the fees within the specified period will result in the company being listed on the FDA's official arrears list, causing significant damage to its credit rating. Furthermore, products produced in non-compliant facilities may be considered misbranded and subject to a severe regulatory action, including a complete ban on distribution in the United States. Therefore, domestic and international pharmaceutical companies participating in the OTC market must closely coordinate between their finance and regulatory affairs (RA) departments to secure budgets in advance and manage schedules thoroughly.
With the U.S. OTC market estimated at approximately $46.62 billion in 2026, the OMUFA II reauthorization and the specification of fees will alleviate financial uncertainties for major OTC companies such as Perrigo and Kenvue. In the short term, the mandatory payment of MDF fees ($19,188) and the ban on distribution for non-payment will make administrative risk management of manufacturing facilities a top priority. In the medium to long term, with Tier 1 OMOR fees increasing to $587,529, the importance of demonstrating clinical validity and safety data will be further emphasized for researchers planning to introduce new ingredients and expand indications. Companies preparing for the final approval stage should proactively reflect OMOR budgets equivalent to the costs of late-stage clinical trials, which will likely result in development capabilities being concentrated on a small number of core pipelines.